Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices 85221 

presentations with audio and video 

components to allow the presentation of 

materials for online participants in a 

manner that most closely resembles an 

in-person advisory committee meeting. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the Committee. All electronic and 

written submissions to the Docket (see 

ADDRESSES) on or before November 19, 

2024, will be provided to the 

Committee. Oral presentations from the 

public will be scheduled following FDA 

presentations. FDA has allotted 

approximately 1 hour for open public 

hearing presentations, which will be 

split to allow for public remarks on each 

substance. The sessions will begin at 

approximately 9:35 a.m., 10:50 a.m., and 

1:40 p.m. Those individuals interested 

in making formal oral presentations 

should notify the contact person and 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, 

whether they would like to present 

online or in-person, and an indication of 

the approximate amount of time 

requested to make their presentation on 

or before November 8, 2024. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. FDA may also 

extend the time scheduled for open 

public hearing presentations depending 

on interest. Similarly, room for 

interested persons to participate inperson may be limited. If the number of 

registrants requesting to speak in-person 

during the open public hearing is 

greater than can be reasonably 

accommodated in the venue for the inperson portion of the advisory 

committee meeting, FDA may conduct a 

lottery to determine the speakers who 

will be invited to participate in-person. 

The contact person will notify 

interested persons regarding their 

request to speak and the timeframe for 

the presentation by November 12, 2024. 

Persons attending FDA’s advisory 

committee meetings are advised that 

FDA is not responsible for providing 

access to electrical outlets. 

For press inquiries, please contact the 

Office of Media Affairs at fdaoma@

fda.hhs.gov or 301–796–4540. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with disabilities. 

If you require accommodations due to a 

disability, please contact Takyiah 

Stevenson (see FOR FURTHER

INFORMATION CONTACT) at least 7 days in 

advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our website at 

https://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. 1001 et seq.). This meeting notice 

also serves as notice that, pursuant to 21 

CFR 10.19, the requirements in 21 CFR 

14.22(b), (f), and (g) relating to the 

location of advisory committee meetings 

are hereby waived to allow for this 

meeting to take place using an online 

meeting platform in conjunction with 

the physical meeting room (see 

location). This waiver is in the interest 

of allowing greater transparency and 

opportunities for public participation, 

in addition to convenience for advisory 

committee members, speakers, and 

guest speakers. The conditions for 

issuance of a waiver under 21 CFR 10.19 

are met. 

Dated: October 21, 2024. 

Eric Flamm, 

Acting Associate Commissioner for Policy. 

[FR Doc. 2024–24828 Filed 10–24–24; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Final Effect of Designation of a Class 

of Employees for Addition to the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice concerning 

the final effect of the HHS decision to 

designate a class of employees from the 

Metals and Controls Corp. in Attleboro, 

Massachusetts, as an addition to the 

Special Exposure Cohort (SEC) under 

the Energy Employees Occupational 

Illness Compensation Program Act of 

2000. 

FOR FURTHER INFORMATION CONTACT: 

Grady Calhoun, Director, Division of 

Compensation Analysis and Support, 

NIOSH, 1090 Tusculum Avenue, MS C– 

46, Cincinnati, OH 45226–1938, 

Telephone 513–533–6800. Information 

requests can also be submitted by email 

to DCAS@CDC.GOV. 

SUPPLEMENTARY INFORMATION: On 

September 9, 2024, as provided for 

under 42 U.S.C. 7384l(14)(C), the 

Secretary of HHS designated the 

following class of employees as an 

addition to the SEC: 

All atomic weapons employees who 

worked at Metals and Controls Corp. in 

Attleboro, Massachusetts, from January 1, 

1968, through September 21, 1995, for a 

number of work days aggregating at least 250 

work days, occurring either solely under this 

employment or in combination with work 

days within the parameters established for 

one or more other classes of employees 

included in the SEC. 

This designation became effective on 

October 9, 2024. Therefore, beginning on 

October 9, 2024, members of this class of 

employees, defined as reported in this notice, 

became members of the SEC. 

Authority: 2 U.S.C. 384q(b). 42 U.S.C. 

7384l(14)(C). 

John J. Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2024–24833 Filed 10–24–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business Innovation Research/Small 

Business Technology Transfer: Clinical Care 

and Health Interventions. 

Date: November 14–15, 2024. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: In Person and Virtual 

Meeting. 


ddrumheller on DSK120RN23PROD with NOTICES1